Table 2.

Categorical secondary outcomes: proportions of patients achieving HbA1c levels < 7.0% and < 8.0% at T0 and T6 (EP and PP populations)

Population	Outcome	T0 (%)	T6 (%)	Absolute pre–post difference (%)	p-valuea
EP	HbA1c < 7.0%	5.4	16.3	+ 10.9	0.0001
PP	HbA1c < 7.0%	7.7	19.7	+ 12.0	0.002
EP	HbA1c < 8.0%	25.5	53.8	+ 28.3	< 0.0001
PP	HbA1c < 8.0%	29.1	59.8	+ 30.7	< 0.0001

^aMcNemar test. Statistically significant p-values (p < 0.05) are in bold

EP efficacy population: subset of the intention-to-treat population (ITT) having HbA1c valid values at T0 and T6; PP per-protocol population: subset of EP patients treated according to summary of product characteristics